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Abstract
Several gastrointestinal and gynecological malignan-
cies have the potential to disseminate and grow in 
the peritoneal cavity. The occurrence of peritoneal 
carcinomatosis (PC) has been shown to significantly 
decrease overall survival in patients with liver and/or 
extraperitoneal metastases from gastrointestinal can-
cer. During the last three decades, the understanding 
of the biology and pathways of dissemination of tumors 
with intraperitoneal spread, and the understanding of 
the protective function of the peritoneal barrier against 
tumoral seeding, has prompted the concept that PC is 
a loco-regional disease: in absence of other systemic 
metastases, multimodal approaches combining aggres-
sive cytoreductive surgery, intraperitoneal hyperthermic 
chemotherapy and systemic chemotherapy have been 
proposed and are actually considered promising meth-
ods to improve loco-regional control of the disease, and 
ultimately to increase survival. The aim of this review 
article is to present the evidence on treatment of PC 
in different tumors, in order to provide patients with a 
proper surgical and multidisciplinary treatment focused 
on optimal control of their locoregional disease.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: This review aims to present the evidence on 
treatment of peritoneal carcinosis in different tumors, 
in order to provide patients with a proper surgical and 
multidisciplinary treatment focused on optimal control 
of their locoregional disease.
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INTRODUCTION
Several gastrointestinal and gynecological malignan-
cies have the potential to disseminate and grow in the 
peritoneal cavity. This condition is often associated with 
disease progression and poor prognosis. The occurrence 
of  peritoneal carcinomatosis (PC) has been shown to 
significantly decrease overall survival in patients with 
liver and/or extraperitoneal metastases from gastrointes-
tinal cancer. Moreover, overall survival in patients with 
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PC is generally only slightly influenced by systemic che-
motherapy, so that the occurrence of  PC is traditionally 
regarded by the surgeon as a terminal condition. 
In 10%-35% of  patients with recurrent colorectal 
cancer (CRC) and in up to 50% of  patients with recur-
rent gastric cancer (GC), tumor recurrence is confined 
to the peritoneal cavity: those patients have been shown 
to ultimately die from complications of  locoregional tu-
moral widespread, in most cases without occurrence of  
metastases in other sites. This natural unfavorable evolu-
tion of  recurrence is commonly observed in epithelial 
ovarian cancer (EOC) too, a condition always associated 
with PC and in which locoregional widespread of  the 
tumor is the most common cause of  death. However, 
while in EOC there is general agreement that complete 
removal of  peritoneal seedings is associated with longer 
survival, in CRC and GC complete removal of  perito-
neal carcinomatosis is usually followed by short-term re-
currence, so that patients are usually treated with limited 
palliative resection or gastrointestinal bypass without the 
intent for complete cytoreduction. 
On the other hand, almost 15% of  patients with 
colorectal cancer and almost 40% of  patients with stage 
Ⅱ-Ⅲ gastric cancer present with PC at abdominal ex-
ploration: in these cases there are no standardized in-
dications for surgery, and operations vary from simple 
exploration and biopsy to palliative resection of  the pri-
mary tumor, the latter procedure being associated with 
wide interruption of  the peritoneal integrity and further 
seeding of  neoplastic cells. 
Preoperative diagnosis of  PC could be very difficult. 
Imaging techniques (mainly based upon computed to-
mography-scan and magnetic resonance imaging), could 
assist in planning cytoreduction but also in preventing 
unwarranted laparotomy in patients with unresectable 
disease. However, they are limited in their ability to vi-
sualize localized PC, having low sensitivity for small-
volume disease. The gold standard in diagnosing PC 
continues to be the direct peritoneal visualization, either 
by laparotomy or laparoscopy. 
During the last three decades, the understanding of  
the biology and pathways of  dissemination of  tumors 
with intraperitoneal spread, and the understanding of  
the protective function of  the peritoneal barrier against 
tumoral seeding, has prompted the concept that PC is 
a loco-regional disease: in absence of  other systemic 
metastases, multimodal approaches combining aggres-
sive cytoreductive surgery (CRS), intraperitoneal hyper-
thermic chemotherapy (HIPEC) and systemic chemo-
therapy have been proposed and are actually considered 
as promising methods to improve loco-regional control 
of  the disease and ultimately to increase survival. Even 
if  evidence of  efficacy of  these multimodal approaches 
comes from several phase-Ⅱ studies, a few phase-
Ⅲ studies have been published for CRC and GC, and 
other are ongoing for EOC. HIPEC privileges consist 
in increasing loco-regional drugs concentration limiting 
their systemic diffusion and consequentially their tox-
icitys and adverse events. The role of  peritoneal plasma 
barrier in promoting a loco-regional high-dose effect is 
very important. Indeed, peritoneum has the capability to 
limit the systemic drugs diffusion in the peritoneal space. 
Moreover, the hyperthermia enhances the efficacy and 
the penetration of  many of  the drugs employed.
The renewed interest on treatment of  PC is going to 
change the attitude of  the surgeon towards tumors with 
peritoneal seeding, thus new paradigms are focusing on 
the proper behavior that the surgeon should adopt when 
PC is encountered during operation. Consideration 
should be given to the different proposed approaches 
facing different degrees of  peritoneal cancer dissemi-
nation, but, above all, the question should be: what 
shouldbe done if  PC is encountered? In presence of  PC, 
therapeutic algorithms should be addressed, taking into 
account the different pathologies and the risk-benefit 
balance.
The aim of  this review article is to present the evi-
dence on treatment of  PC in different tumors and to 
give indications to surgeons who deal with patients with 
PC, in order to provide patients with a proper surgical 
and multidisciplinary treatment focused on optimal con-
trol of  their locoregional disease.
ROLE OF CYTOREDUCTIVE SURGERY 
AND HIPEC IN THE TREATMENT OF 
ABDOMINAL CARCINOMATOSIS FROM 
DIFFERENT PRIMARY MALIGNANCIES
Biological research has identified three pattern of  peri-
toneal cancer spread: (1) random proximal distribution 
(RPD), in which early peritoneal implantation is due 
to the presence of  adherence molecules on cancer cell 
surface, even when ascites is present; this is typical of  
moderate-grade and high-grade cancers, such as adeno-
carcinoma and carcinoid of  the appendix, non-mucinous 
colorectal cancer, gastric cancer and serous ovarian can-
cer; (2) complete redistribution (CRD), in which there 
is no adhesion to the peritoneal surface close to the 
primary tumor, due to the low biologic aggressiveness 
of  tumor cells; this distribution is typical of  pseudo-
myxoma peritonei and diffuse malignant mesothelioma; 
and (3) widespread cancer distribution (WCD), in which 
there is presence of  adherence molecules on the surface 
of  cancer cells that produce a great amount of  mucus, 
interfering with cell adherence: this biological behavior is 
found in aggressive and undifferentiated tumors such as 
G2-G3 cistoadenocarcinoma of  the appendix, mucinous 
colorectal cancer and mucinous ovarian cancer. 
Information about patterns of  spread are very im-
portant to plan the best surgical treatment. In fact, while 
RPD should be treated by a selective parietal peritonec-
tomy of  the macroscopically involved regions, for CRD 
and WCD a complete peritonectomy and an extended 
cytoreduction are needed[1].
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PERITONEAL MESOTHELIOMA
Malignant mesothelioma is an uncommon tumor arising 
from the serosal layer of  pleura, peritoneum, pericar-
dium and tunica vaginalis testis. 
The incidence of  this disease has been rising world-
wide since 1970, due to widespread exposure to asbes-
tos during previous decades, and it is not expected to 
decrease before the next 20 years. In the United States, 
approximately 2500 new cases of  mesothelioma are reg-
istered each year. Diffuse malignant peritoneal mesothe-
lioma accounts for 10% to 30% of  all mesotheliomas. 
Despite the absence of  randomized studies, which 
are obviously difficult in a rare disease, clinical results 
obtained with the combination of  CRS and HIPEC sup-
port the adoption of  this procedure as a treatment of  
choice for peritoneal mesothelioma. 
In historical series, standard therapy with palliative 
surgery and systemic chemotherapy is associated with 
a median survival of  about one year, ranging from 9 to 
15 mo. Whit such a classical approach, the disease tends 
to remain within the abdominal cavity throughout its 
clinical course; an autopsy study demonstrated that 78% 
of  patients had died because of  complications directly 
related to local-regional progression .
On the contrary, Yan et al[2] in a recent multi-institu-
tional study examined 407 patients affected by peritoneal 
mesothelioma treated with CRS and HIPEC in 7 differ-
ent surgical centers. The mean age of  the patients was 
50 years, 89% of  the cases were epithelial mesothelioma 
while 11% were sarcomatoid or bifasic. CC0-CC1 rates 
was achieved in 46% of  cases, lymph nodes metastases 
were find in 6% and distant metastases in 3% of  the 
patients. After a mean follow up of  30 mo, the median 
survival was 53 mo. A multivariate analysis showed as 
independent prognostic factor the histological type of  
the mesothelioma, the level of  cytoreduction achieved, 
lymph node metastases, and the possibility to perform 
HIPEC.
PRIMARY PERITONEAL CARCINOMA
Primary peritoneal carcinoma (PPC), was described for 
the first time by Swerdlow[3]. Its pathogenesis has been 
controversial. Some Authors believe that PPC develops 
from a malignant transformation of  embryonic germ 
cell nests cells[4], other from the celomic epithelium lin-
ing the abdominal cavity (peritoneum) and the ovaries 
(germinal epithelium), manifesting a common response 
to an oncogenic stimulus[5]. A multifocal origin have 
been suggested by Muto et al[6] with clonality studies, 
while other authors suggest an unifocal origin[7]. 
Even if  from an histological and a clinically point 
of  view PPC is similar to advanced epithelial ovarian 
cancer, it diffusely involves the peritoneum by papillary 
carcinoma in the absence of  an obvious primary site 
and grossly normal ovaries[8]. It accounts for 10% of  all 
pelvic serous carcinomas. Most reported cases of  PPC 
have been described in women, usually elderly; however, 
rare cases have been reported in children and males. His-
tologically most reported PPC cases are primary perito-
neal serous papillary carcinoma, while rarely are they are 
described as peritoneal mixed epithelial carcinoma and 
malignant mixed Mullerian tumor.
The prognosis of  PPC is poor, the median survival 
time ranging between 7 and 27.8 mo; 5-year survival 
rates range from 0% to 26.5%[9].
PPC diagnosis cannot be easily made preoperatively, 
being typically made by exclusion after both operative as-
sessment and pathological study. In fact if  ovaries seem 
normal with widespread disease elsewhere in the abdo-
men, PPC may be considered as a diagnostic possibility. 
However, because surface involvement of  the ovaries is 
present in approximately 96% of  the cases, the distinc-
tion between extra ovarian primary peritoneal cancer 
and epithelial ovarian carcinoma may only be made after 
histological examination to evaluate the extent of  ovar-
ian invasion by tumor[10].
Therefore, surgery remains critically important for 
both diagnosis and therapy of  PPC. Once the diagnosis 
has been established and the extent of  disease docu-
mented, maximal cytoreduction becomes the primary 
goal of  the procedure. Excision of  all visible implants 
is the hallmark of  cytoreductive efforts. To the best of  
our knowledge, no study has been conducted assessing 
the efficacy of  CRS with HIPEC for this kind of  car-
cinomatosis, even if  it is reasonable that this approach 
should be taken in consideration in the contest of  clini-
cal studies.
PSEUDOMYXOMA PERITONEI 
Pseudomyxoma peritonei (PMP), a syndrome firstly 
described by Rokitansky in 1842, is an enigmatic, often 
fatal intra-abdominal disease characterized by gelatinous 
ascites and multifocal peritoneal epithelial implants se-
creting copious globules of  extracellular mucin. This 
condition is almost always due to a perforated epithe-
lial appendix cancer. Three pathologic variant of  PMP 
are known: disseminated peritoneal adenomucinosis 
(DPAM), peritoneal mucinous carcinomatosis (PMCA), 
and peritoneal mucinous carcinomatosis with intermedi-
ate or discordant features. 
The natural history of  this disease has been drastical-
ly changed by the introduction of  CRS combined with 
HIPEC. Ronnett et al[11] found a significant difference in 
the prognosis of  patients affected by this three different 
form of  PMP. The most important prognostic variable 
affecting 10 years survival rates are the possibility to 
achieve CC0-CC1 (the more the complete cytoreduc-
tion, the longer the survival) and the pathological feature 
of  PMP. Deraco et al[12] reported an overall 10 years 
survival rate of  78.9% in patients affected by PMP and 
treated with CC0-CC1 CRS, while no patient with CC2-
CC3 CRS survived 10 years. Patients affected by DPAM 
had a 10 years survival of  67% while those affected by 
PMCA had no more than 40.7% 10 years survival rate. 
Baratti et al[13] recently published a study on prognostic 
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value of  serum tumor markers in patients with PMP un-
dergoing CRS and HIPEC. It is clear that pre-operative 
normal values of  C385 were statistically related to the 
ability to perform an adequate cytoreduction and that 
elevated pre-operative values of  C17.9 were associated 
with reduced progression-free survival. CEA has also 
been shown to have good sensitivity in case of  progres-
sion. Chua et al[14] published the results of  a retrospec-
tive multi-institutional study. The purpose of  this study 
was to evaluate outcome and long-term survival after 
CRS and HIPEC in PMP patients. The registry included 
2296 patients from 16 centers with a mean PCI of  20, 
CCR0/1 was achieved in 83%, mortality was 2% and 
major morbidity was 24%. Median survival was 196 mo, 
disease free median survival was 98 mo, and 10 and 15 
years survival was respectively 63% and 59%. Multivari-
ate analysis have identified as negative prognostic factor 
for overall survival: previous chemotherapy courses, 
PMCA histological type, major postoperative complica-
tion, CCR 2/3, older age, while negative prognostic fac-
tor for progression free survival were all the above plus 
high peritoneal cancer index and not using HIPEC.
PERITONEAL CARCINOMATOSIS FROM 
GASTRIC CANCER
Penetration of  the gastric serosa and lymphatic spread 
are the two most important factors affecting prognosis 
in gastric cancer (GC)[15-17]. When the gastric serosa is 
infiltrated by tumor, PC becomes pravery frequent[18]. 
Subsequently, up to half  of  the patients with advanced 
gastric cancer (AGC) will develop a peritoneal carcino-
matosis in spite a radical surgery[19-22], and PC is quite 
common in gastric cancer, being already present in 
5%-20% of  patients explored for potentially curative 
resection[18,23]. There are several methods for detecting 
the presence of  free peritoneal tumor cells (FPTC) with 
different sensitivity[24-26]. FPTC in the washing could be 
identified in up to 24% of  stage IB and up to 40% of  
stage Ⅱ or Ⅲ GC patients[27]. Moreover, after radical re-
section, the peritoneum is the only site of  recurrence in 
10%-34% of  cases, and one of  the recurrences sites in 
29%-44% of  cases[28-32].
The five-year survival rate in patients with peritoneal 
carcinosis from GC (PCGC) is lower than 3%[33], with an 
overall mean and median survival of  6.5 and 3.1 mo, re-
spectively[34]. Among the non-gynecologic malignancies, 
PCGC has a better prognosis than PC from pancreatic 
cancer but worse than PC from CRC[34]. Saito et al[35] re-
ported a 5-year survival rate of  advanced GC with FPTC 
of  15.3%, similar to that of  patients having macroscopi-
cal peritoneal metastasis (14.8%). As a counterpart, there 
are no 5-year survivors among patients with distant peri-
toneal metastases. 
Systemic chemotherapy may improve median sur-
vival up to 12 mo in advanced/metastatic GC[36-39], but 
a similart survival benefit has not been reported in mac-
roscopic PC[40-43]. One possible explanation seems to be 
that systemic chemotherapy inadequately reaches the ab-
dominal cavity[44]. Yonemura et al[45] demonstrated a sur-
vival benefit by treating patients with PFTC with radical 
resection followed by adjuvant systemic chemotheraphy. 
Patients treated with adjuvant chemotherapy survived 
significantly longer than patients in control group: the 1 
and 2-year survival rates were 88% and 44%, and 53% 
and 9%, in adjuvant group and control group, respec-
tively. The mean overall survival was 21.1 and 9.1 mo for 
adjuvant and control group (P < 0.05). The ineffective-
ness of  systemic chemotherapy in PC may be related 
to a number of  factors, such as the peritoneal-plasma 
barrier, the intraperitoneal poor blood supply and oxy-
genation of  cancer cells, and the low apoptotic potential 
of  such hypoxic tumor cells[37,46-48]. Neoadjuvant chemo-
therapy (NACT) has been described to decrease the load 
of  macroscopic PCGC[37,49]. Yano et al[50] reported a small 
series of  4 out of  26 (15.4%) patients affected by PCGC 
with complete remission of  peritoneal metastasis with 
after NACT. All these patients subsequently underwent 
curative resection. Inokuchi et al[51] reported a partial 
response in 9 out of  13 patients (69%). However,one 
further study suggests that after NACT the detection 
of  FPTC can change from positive to negative and vice 
versa. This change is not linked to the response to the 
systemic chemotherapy. Ten out of  42 (24%) patients 
with negative peritoneal cytology shifted into positive 
for FPTC during NACT, while 7 out of  19 (37%) with 
FPTC positive cytology at staging laparoscopy turned 
negative[52].
GC peritoneal spread remains a major problem, and 
some Authors finally suggest that there is no role for 
surgery in PCGC[53]. Since the 80s, Japanese surgeons 
combined CRS, regional hyperthermia and intraperi-
toneal chemotherapy in a multimodal approach[54]. As 
for other types of  PC, in GC HIPEC after CRS is ac-
complished to eliminate FPTC and to prevent or delay 
PC[53,55]. A number of  studies have been conducted, with 
the aim to demonstrate a significant reduction in the 
rate of  subsequent PC and an increase in survival of  
patients with AGC when radical surgery was combined 
with HIPEC[20,56-61]. Yonemura et al[62] demonstrated that 
HIPEC could improve significantly the median survival 
from 15 to 48 mo and the 5-years survival rate from 12% 
to 42% in patients with PFTC. On the other hand, the 
combined CRS and HIPEC treatment of  PCGC seems 
to be the one with less encouraging results in terms of  
survival and of  morbidity and mortality when compared 
to other types of  PC[63,64]. A French retrospective, multi-
center study published in 2010 evaluated toxicity and sig-
nificant prognostic factors after CRS and HIPEC (and/
or early postoperative intraperitoneal chemotherapy, 
EPIC) for PC from nongynecologic neoplasms[65]. The 
study involved 1290 patients from 25 French institutions 
who underwent 1344 CRS procedures between 1989 
and 2007. HIPEC was made in 1154 cases (86.4%). The 
principal origin of  PC was CRC (n = 523, 40.5%), and 
no more than 159 GC cases were present in this series 
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(12.3%). The whole group overall 3- and 5-year survival 
rates were 49% and 37% respectively. The PCGC group 
showed the worse outcome with a 3- and 5-year survival 
rates of  18% and 13%, respectively. The overall median 
survival of  the whole group and of  the PCGC group 
were 34 and 9 mo respectively. Li et al[66] from China 
reported in 2010 a series of  128 patients with PCGC. 
Fifty-four (42.2%) underwent gastrectomy, and 10 un-
derwent resection with HIPEC. The other 74 (57.8%) 
received non-resection surgery. The median survival in 
the unresected group was 6 mo compared to 11.8 mo 
of  the resected patients. Moreover, they observed a sig-
nificantly improved survival in the patients treated with 
surgery and HIPEC compared to those treated with sur-
gery alone[67]. Post-operative complications were more 
frequent in the HIPEC than in the resection alone group 
(20.0% vs 13.2%, P = 0.34). Yang et al[68] published the 
final results of  a phase Ⅲ randomized trial, performed 
in China in order to evaluate the efficacy and safety 
of  CRS plus HIPEC for the treatment of  PCGC. The 
median overall survival was 6.5 mo in CRS alone group 
and 11 mo in the CRS + HIPEC group (P = 0.046). 
This outcome was even more significant in patients with 
synchronous PCGC (n = 51), being the median overall 
survival 12 mo in CRS + HIPEC group (n = 24) and 6.5 
mo in the CRS group (n = 27, P = 0.029). The 1-, 2-, and 
3-year survival rates were 29.4%, 5.9% and 0% for CRS 
group, and 41.2%, 14.7% and 5.9% for CRS + HIPEC 
group, respectively. The CC-score has been demon-
strated to influence survival, but HIPEC obtained a sig-
nificant advantage both in CC 0-1 and CC 2-3 patients. 
In the CRS + HIPEC patients, the median overall sur-
vival in CC 0-1 (n = 20) and in CC 2-3 subgroups (n = 
14) was 12 and 8.2 mo respectively. In CRS patients, the 
median overall survival in CC 0-1 (n = 20) and in CC 2-3 
subgroup (n = 14) was 11 and 4 mo respectively. Serious 
adverse events arose in 9 patients, 4 in the CRS group 
(11.7%) and 5 in the CRS + HIPEC group (14.7%) (P = 
0.839). Multivariate analysis recognized CRS + HIPEC, 
synchronous PC, CC 0-1, systemic chemotherapy and no 
serious adverse events as major independent predictors 
for better survival. HIPEC was about 2.6 times likely to 
increase survival.
Gill et al[67] published a systematic review analyzing 
survival, mortality and morbidity in the treatment of  
PCGC with CRS and HIPEC. Ten studies were included. 
Overall median survival was 7.9 mo. In the subgroup of  
patients with residual nodules after CRS, less than 0.25 
cm in size, the median survival raised up to 15 mo. The 
1- and 5-year survival were 43% and 13%. The treat-
ment-related mortality rate was 4.8% and the morbidity 
was 21.5%.
Recently, Yonemura et al[61], proposed a multimodal 
strategy which associates neoadjuvant intraperitoneal 
and systemic chemotherapy (NIPS), CRS + HIPEC and 
early postoperative intraperitoneal chemotherapy (EPIC). 
The rationale of  this method is to reduce tumor burden 
before surgery with NIPS, a bidirectional chemotherapy 
that attacks PC from both sides of  peritoneum (from the 
peritoneal cavity and from sub-peritoneal blood vessels), 
and reducing macroscopic and microscopic PC with 
CRS + HIPEC. At the end, the use of  EPIC is proposed 
to eradicate residual intraperitoneal cancer cells before 
fibrin and adhesion development. Authors recommend 
two cycles of  NIPS to achieve a negative cytology status. 
Severe complication post-NIPS have been reported in 
4 out of  79 patients. This strategy allowed to obtain a 
change in washing cytology from positive to negative in 
41 out of  79 patients (63%). 
Three recent meta-analysis of  randomized trials 
analyzing patients with advanced GC (with or with-
out PC) demonstrated the survival benefit offered by 
HIPEC[69-71]. 
In the last ten years, a new drug for intraperitoneal 
treatment of  GC has been developed in Germany. Catu-
maxomab (trade name Removab®) is a rat-mouse hybrid 
monoclonal antibody that is made up of  one “half ” (one 
heavy chain and one light chain) of  an anti-Epithelial 
cell adhesion molecule (EpCAM) antibody and one half  
of  an anti-CD3 antibody, thus finally binding both Ep-
CAM and CD3. EpCAM is an epithelial differentiation 
antigen that is expressed on normal epithelial cells and 
on almost all carcinomas (especially gastrointestinal and 
ovarian carcinomas) and functions as cell adhesion mol-
ecule[72]. In addition, the Fc-region can bind to an Fc re-
ceptor on accessory cells like other antibodies, which has 
led to calling the drug a trifunctional antibody. Actually 
Catumaxomab is used to treat malignant ascites, because 
of  the intraperitoneal application of  this anti-EpCAM 
antibody has shown significant benefits in puncture-
free survival (survival without repeated paracentesis) for 
patients with malignant ascites in a phase Ⅲ random-
ized trial[73]. This study demonstrated no statistically 
significant increases in median overall survival for other 
cancers, while in patients with GC a small survival in-
crease was associated with the use of  Catumaxomab[73]. 
Progression-free survival has been analyzed in a phase 
Ⅱ studie with the use of  intraperitoneal catumaxomab 
in gastrointestinal EpCAM+ tumors[74]. Furthermore two 
phase 2 studies are ongoing (follow-up phase), evaluating 
resectable advanced GC patients treated with adjuvant 
intraperitoneal Catumaxomab. 
In conclusion, in PCGC CRS and HIPEC proved 
with good evidence to improve survival with acceptable 
morbi-mortality. It is very important to obtain the diag-
nosis and the diffusion grade of  PCGC before the CRS 
and HIPEC with the use of  staging laparoscopy. The 
role of  surgery is fundamental, complete cytoreduction 
demonstrated to be strictly related to an improvement in 
survival. In patients with PCGC, multimodal treatment 
should be mandatory, leaving a pivotal role to HIPEC 
after CRS.
PERITONEAL CARCINOMATOSIS FROM 
OVARIAN CANCER
Nowadays, the treatment diagram for advanced EOC 
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has been universally accepted as a combination of  maxi-
mal CRS and adjuvant chemotherapy, including cases 
with grossly peritoneal diffuse disease. Grade ⅢC and 
Ⅳ are no longer considered as “lost”. Different studies 
demonstrated that a progressively more aggressive surgi-
cal effort is associated with improvements in disease-free 
and overall survival rates. It is suggested that aggressive 
surgery should be performed in dedicated centers with 
high volume of  cases, offering in-hospital mortality sig-
nificantly lower than low volume ones[75]. The more the 
surgeon became radical and increases his/her surgical 
volume, the more he/she prolongs the disease-free and 
overall survival and reduces the in-hospital mortality. As 
a counterpart, the tumor biology and the initial disease 
diffusion have been suggested as the most important fac-
tors in survival benefit of  surgery[76-79]. It’s still undefined 
how the intrinsic features of  the tumor make intra-ab-
dominal implants easier to remove[80]. In general, upper 
abdominal tumor implants are suggestive of  an aggres-
sive tumor biology[81]. Covens and Berman criticized the 
role of  CRS in advanced EOC. They proposed that both 
survival and surgical resectability are mostly determined 
by tumor biology instead of  the operative effort by the 
surgeon[82,83]. The retrospective review of  data from the 
Scottish Randomized Trial in Ovarian Cancer revealed 
in a population of  889 patients with disease stage rang-
ing from IC to Ⅳ that the benefit of  optimal debulking 
surgery seems to depend from the extent of  disease be-
fore surgery[79]. Hager et al[84] analyzing 456 women with 
advanced stage Ⅲ/Ⅳ ovarian cancer, demonstrated no 
correlation between nodal status and survival. Moreover 
in advanced EOC nodal status was not a prognostic fac-
tor for patients undergone to optimal cytoreduction.
Complete cytoreduction is reached when no visible 
tumor remains after the surgical procedure. Starting 
from this classification a number of  prospective and 
retrospective studies have been conducted to investigate 
the feasibility and the impact on survival of  CRS in ad-
vanced EOC.
Up to now, the majority of  available series report 
cases treated with the standard systemic platinum-tax-
anes chemotherapy and CRS. Only one study analyzed 
cases treated also with intraperitoneal chemotherapy[85].
Between 2003 and 2010, 15 studies have been pub-
lished analyzing patients treated with CRS and systemic 
chemotherapy for advanced EOC. The overall survival 
(OS) ranges between 46.5 and 106 mo for patients with 
complete CRS (no residual disease) and between 12 and 
39 mo for incomplete CRS (residual disease of  more 
than 1 cm)[85-92]. All these papers demonstrated that CRS 
plays a central role in advanced EOC treatment. The 
necessity of  adjuvant chemotherapy has already been 
demonstrated. Surgical effort must be absolute. 
Between 2000 and 2010, 20 observational studies 
have been published about CRS + HIPEC in treating 
PC from advanced and recurrent EOC. The first was 
published by Cavaliere et al[93] reporting about 20 patients 
with recurrent EOC. They reported a median OS of  25 
mo with a 3-year survival of  50%.
De Bree et al[94] and Chatzigeorgiou et al[95] reported 
about 19 and 20 patients respectively with recurrent 
ovarian cancer. They found  median DFS of  26 and 21 
mo, respectively. De Bree reported a median OS of  54 
mo and Chatzigeorgiou a median OS for optimally cyto-
reducted patients (considered as residual disease of  < 1.5 
cm) of  29 mo. De Bree found a 3 and 5 year survuival 
of  63% and 42%. Both studies reported a perioperative 
mortality rate of  about 10%.
Four studies have been published in 2004[96-98]. Zanon 
et al[96] described a cohort of  19 patients with recurrent 
EOC. They reported a median DFS of  17 mo with a 
median OS and OS in optimally cytoreducted patients 
(residual disease < 0.25 cm) of  28 and 38 mo respectively. 
Three and 5-year survival were 35% and 12% respectively. 
Perioperative mortality rate was 3 % with grade 1 or 2 
morbidity rate of  27% and 3% respectively and with grade 
3 and 4 morbidity of  7%.
Piso et al[97] reported a series of  19 patients with peri-
toneal carcinomatosis due to primary or recurrent EOC. 
The median DFS was 18 mo, with mean OS and OS in 
optimally cytoreducted patients (residual disease < 0.25 
cm) of  33 and 44 mo respectively and a 5-year survival 
rate of  15%. Perioperative mortality rate was 3%, grade 
1-2 morbidity rate was 10% and grade 3-4 morbidity of  
10% and 15% respectively[97].
Ryu et al[98] reported a series of  57 patients with ad-
vanced EOC. The median DFS was 26 mo. Median OS 
in optimally cytoreduced patients (residual disease < 1 
cm) was 41 mo. The OS at 5-year was 54%. The survival 
advantage has been found to be more pronounced in 
stage 3 disease. Multivariate analysis showed HIPEC as 
an independent prognostic factor. Perioperative mortal-
ity was 4 % with grade 1, 2 and 4 morbidity rate of  14%, 
5% and 4%, respectively.
Gori et al[99] and Reichman et al[100] reported about 29 
and 13 patients respectively with advanced EOC. Me-
dian DFS were 15 and 11 mo respectively, with a median 
OS in Gori’s paper of  64 mo and a 3-year survival rate 
in Reichman’s study of  55%. None of  these two studies 
reported morbidity nor mortality.
Raspagliesi et al[101] and Rufián et al[102] published two 
reports with 40 and 33 patients respectively, with ad-
vanced and recurrent EOC. Median DFS and OS in the 
first paper were 11 and 32 mo, and median OS and OS 
in optimally cytoreduced patients (residual disease < 1 
cm) were 48 and 66 mo respectively. Five-year survival in 
Raspagliesi’ series was 15%; 3 and 5-year survival rate in 
Rufian study were 46% and 37%, respectively. Reported 
mortality for both papers was 0%. Raspagliesi reported 
20% of  grade 1 morbidity. Rufian reported grade 1 and 
2 morbidity rate of  12% and 10% and grade 3 and 4 
morbidity of  10% and 6% respectively.
Helm et al[103], Cotte et al[104] and Bae et al[105] published 
series of  18, 81 and 67 patients with recurrent (Helm 
and Cotte) and advanced EOC (Bae). Helm et al[103] re-
ported a median DFS of  10 mo and median OS and OS 
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in optimally cytoreduced patients (residual disease < 0.5 
cm) was 31 and 31 mo respectively Perioperative mortal-
ity was 6% and grade 1, 2, 3 and 4 complications have 
been reported in 11%, 50%, 40% and 13% of  patients 
respectively. 
Cotte et al[104] described a median DFS of  19 mo and 
an OS and OS in optimally cytoreduced patients (residual 
disease < 0.25 cm) of  28 and 55 mo respectively. Peri-
operative mortality was 3% and grade 1, 2, 3 and 4 com-
plications have been reported in 6%, 1%, 5% and 2% of  
patients respectively.
Bae et al[105] reported a 5-year survival rate of  66%, 
with a 0% perioperative mortality and grade 1, 2, 3 and 4 
morbidity rate of  14%, 13%, 0% and 0%, respectively. 
Di Giorgio et al[106] published data about 47 patients 
with advanced and recurrent EOC. They reported a 
median DFS of  20 mo with an OS and OS in optimally 
cytoreduced patients (residual disease < 0.25 cm) of  24 
and 26 mo respectively. Five-year survival rate was 17% 
and perioperative mortality 4%. Grade 2, 3 and 4 com-
plication rate were 21%, 9% and 13% respectively.
Bereder et al[87], Guardiola et al[107], Fagotti et al[108], 
Pavlov et al[109] described results of  CRS + HIPEC in ad-
vanced and recurrent EOC and in recurrent EOC.
Guardiola et al[107] published a series of  47 patients 
with a median DFS of  14 mo and a 5-year survival of  
63%. Perioperative mortality rate was 0% and grade 4 
complication rate was 13%. Fagotti et al[108] reported a 
median DFS of  10 mo, with 0% perioperative mortality 
and grade 2, 3 and 4 complication rate 36%, 8% and 8% 
respectively. Pavlov et al[109] described 56 patients with a 
median DFS and OS of  26 and 38 mo respectively. Peri-
operative mortality was 2% and grade 1, 2 and 4 compli-
cation rate were 5%, 11% and 2% respectively. Bereder 
et al[87] published the widest series reporting about 246 
patients with advanced and recurrent EOC. Median DFS 
was 13 mo, median OS and OS in optimally cytoreduced 
patients (residual disease < 0 cm) were 49 and 56 mo re-
spectively. Three and 5-year survival were 60% and 35%. 
Reported intraoperative mortality was 0.4% and grade 3 
morbidity 12%. 
Lastly, Deraco et al[110] published a multi-institutional 
phase 2 study evaluating the impact of  CRS + HIPEC 
as upfront treatment on PFS and OS in 26 women 
with stage 3-4 advanced EOC. All enrolled patients un-
derwent CRS, followed by HIPEC. Patients were then 
treated with adjuvant systemic chemotherapy. Macro-
scopically complete cytoreduction was achieved in 57% 
of  patients, with minimal residual disease (≤ 2.5 mm) 
remaining in the other 43%. Five-year OS was 60.7% 
and 5-year DFS 15.2%. Excluding operative death, all 
the patients underwent a median of  6 cycles of  systemic 
chemotherapy at a median of  46 d from combined treat-
ment. Four patients experienced ≥ grade 3 morbidity, 
with one post-operative death due to sepsis.
Globally, 7 randomized controlled trials evaluating 
the effectiveness of  HIPEC in advanced and recurrent 
OEC have been proposed: five are already ongoing[111-115] 
and two have been only proposed[116].
Ansaloni et al[117] reported about 39 patients with ad-
vanced and recurrent EOC. The mean DFS was 14 mo. 
Grade 1-3 post-operative complications occurred in 18% 
of  patients. Perioperative mortality was 0.3%. 
In conclusion, despite the lack of  high evidence data 
that will be brought from the ongoing randomized trials, 
HIPEC associated to complete CRS seems to give sur-
vival results comparable to the standard treatment. Data 
are still heterogeneous due to the different meaning 
given to the completeness of  cytoreduction, as showed 
in all the aforementioned studies. Some centers consider 
cytoreduction complete when there is no macroscopic 
residual disease, others follow more permissive limits. 
Moreover, confusion exists about “optimal” and “com-
plete” cytoreduction. However, data clearly show as in 
patients with no macroscopic residual disease CRS + 
HIPEC increases the survival rates. These results could 
be overcome in terms of  surgical effort and morbidity 
rate reduction by the use of  NACT.
PERITONEAL CARCINOMATOSIS FROM 
COLO-RECTAL CANCER 
The multi-disciplinary treatment of  CRC is actually stan-
dardized up to stage ⅢC[118-120], while it is unclear and not 
supported by strong evidences for stages Ⅳa and Ⅳb. 
American guidelines from NCI recently consider liver re-
section as available treatment for Ⅳa stage, but they don’t 
mention nowadays HIPEC as treatment option for Ⅳb 
CRC, including the peritoneal carcinomatosis (PCCRC).
Another way to assess the actual relationship be-
tween HIPEC for PCCRC and Evidence Based Medi-
cine is to measure the percentage of  ongoing trials from 
the NCI database: worldwide, among 239 active regis-
tered trials on Ⅳb stage CRC, only eight include HIPEC 
as keyword (2 phase Ⅲ, 4 phase Ⅱ and 2 phase Ⅰ trials: 
from www.cancer.gov, consulted 26th of  June 2013). The 
only concluded randomised clinical trial comparing sys-
temic chemotherapy with cytoreduction plus HIPEC is 
the Dutch trial published in 2003[121]: 105 patients with 
PCCRC without evidence of  hematogenous metastases 
enrolled between 1998 and 2001 were randomly allocat-
ed to receive 5-fluorouracil and leucovorin with or with-
out palliative surgery or “aggressive” cytoreduction plus 
HIPEC followed by the same chemotherapy regimen. 
They demonstrated a median overall survival of  22.3 
mo for the HIPEC arm against 12.6 mo for the stan-
dard therapy, with a significant difference (P = 0.032). 
Unfortunately, the value of  this RCT is limited by sever-
al factors: it was based on a chemotherapy scheme that 
is not the actual gold standard (not including i.e., Irino-
tecan and Oxaliplatin); appendiceal (n = 18) and rectal 
(n = 12) tumors were not balanced in the two groups; 
the HIPEC protocol was based only on mitomycin C in 
the perfusate; the role of  surgery in the control arm was 
unclear and impossible to determine on available data. 
Another randomized trial was designed by Elias to com-
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pare early postoperative intraperitoneal chemotherapy 
plus systemic chemotherapy with chemotherapy alone 
after complete cytoreductive surgery for the PCCRC 
treatment. In 2000, after 4 years and only 35 patients 
enrolled, the study was stopped and the partial results 
analysis did not demonstrate any advantage in term of  
survival[122].
Another attempt to design a RCT comparing stan-
dard systemic therapy with CRS + HIPEC + chemo-
therapy is the USMCI8214/ACOSOG Z6091 trial[123], a 
well designed study, trying to overcome the Dutch trial 
limitations, with a specific target population (peritoneal 
carcinomatosis only, colon cancer) and using advanced/
state-of-the-art chemotherapy. This trial recently closed, 
failing to meet accrual and amplifying the concerning 
from Elias et al[122] about the feasibility of  this kind of  
studies: basically, even if  few trials are active nowadays 
(in particular the last could be the PRODIGE 7 French 
trial[124], with 150/280 patients enrolled at January 2012), 
the idea to get a level of  evidence Ⅰa/Ⅰb in support of  
HIPEC for PCCRC is near to be abandoned.
Anyway, the Dutch study was the base for several 
other trials more adequate and focusing on singular as-
pect, but without the same level of  evidence: in particu-
lar three case control studies (evidence Ⅲa) have been 
published between 2009 and 2011. Elias et al[125] had the 
merit to include the oxaliplatin at 460 mg/m2 dose in 
the perfusate, plus Irinotecan in 18/48 patients, com-
paring the HIPEC group with a standard therapy based 
on 5-fluorouracile (5-FU), folinic acid and systemic 
postoperative oxaliplatin (OX) or Irinotecan (IRI). They 
reached the impressive median survival of  63 mo, with 
a 5-year survival rate of  51% for the HIPEC group pa-
tients with a complete CRS. Franko et al[126] compared 67 
patients treated with mitomycin C-based HIPEC with 38 
controls and all the 105 patients received 5-FU, IRI, OX 
and bevacizumab/cetuximab. Unfortunately they includ-
ed patients with liver metastases and the use of  OX and 
target therapies was greater in the HIPEC group (78% vs 
18% and 59% vs 18% respectively). Chua et al[127] includ-
ed 294 patients, comparing supportive care and pallia-
tion with postoperative systemic chemotherapy based on 
5-FU, IRI, OX, Capecitabine and monoclonal antibodies, 
with or without HIPEC (low-dose mitomycine C) and 
EPIC (high dose 5-FU). The difference between curative 
or palliative therapy was based on preoperative assess-
ment of  the Peritoneal Surface Disease Severity Score
Among not randomized, retrospective multi-institu-
tional studies, the largest published series comes from 
the French registry, including 523 patients with PCCRC 
treated from 1990 to 2007 with CRS and HIPEC[128]. 
Even if  a 16% of  incomplete CRS, with macroscopic 
residual (CCR-1) makes it difficult to extrapolate data 
about survival and the great number of  participants 
centres adds variability (relating in particular to learn-
ing curve and surgical standardization), the reported 
30-d mortality was only 3%, absolutely lower than in the 
Dutch trial (8%).
The peritoneal cancer index (PCI) is a semi-quanti-
tative powerful tool, easily reproducible and validated by 
several studies and expert consensus[129-132], which aims 
at defining and measuring the peritoneal involvement. 
However, using PCI to select PCCRC patients and to 
guide the therapeutic strategy need some comments: a 
threshold value to get a formal contraindication to CRS 
+ HIPEC is not available today; a PCI greater than 20 
is associated with a worse prognosis, even if  in a small 
series (24 patients). Elias et al[133] described a significant 
advantage in survival even when PCI was over 24; for 
PCI < 10, there is agreement about the usefulness of  
CRS + HIPEC, and the median survival for these pa-
tients ranges from 31 to 48 mo[128,134-136]; similar data are 
provided by Gilly et al[137]; in currently active trials a high 
PCI value is generally not an exclusion criteria; different 
studies from the same center stressed the difference be-
tween the PCI declared at the beginning and at the end 
of  surgery, suggesting to systematically add 2 point at 
the preoperative score[138]; Sugarbaker et al[139] suggest to 
correlate PCI with patients demographic when deciding 
to add or not HIPEC to their therapeutic scheme.
Pioneering studies about chemotherapeutic agent 
penetration in the tumor were available since early 
90s[140,141] and have recently been confirmed[142], show-
ing, for example, a diffusion depth of  about 1-2 mm for 
Mitomycin C[143]. Nevertheless, even if  the rationale is 
something more than the common principle of  resect as 
more tumor as possible, the attitude to consider useful 
HIPEC only after an adequate CRS is a recent acquisi-
tion. Moreover, there is no accordance on the dimen-
sional cut-off  (1, 2.5 or 5 mm) and in different series the 
impact of  CCR on survival varies enormously[129,131,136,144]. 
In particular, if  the role of  macroscopic residual (CCR-2) 
nodules seems clear and formally contraindicate HIPEC, 
it is unclear the difference between nothing (CCR-0) 
and very small nodules (up to 2.5 mm, CCR-1 in some 
series). Indeed, even in CCR-1 cases, CRS + HIPEC was 
reported to be related to a better prognosis[134,145-147]. 
Surprisingly, the tumor progression during neo-
adjuvant chemotherapy is not demonstrated to be an 
independent prognostic factor as for gastric cancer with 
PC and actually is not a formal contraindication to CRS 
+ HIPEC[148,149].
As for other organs and pathologies, in the treatment 
of  PCCRC the acronym HIPEC correlate to a wide 
spectrum of  possible variation in temperature, mol-
ecules, concentration and contact time[129,131,134,145,146,150,151]. 
The associated systemic chemotherapy is highly variable 
too. This great number of  parameters makes a standard-
ization difficult: the statement from Elias et al[124] on the 
necessity to follow the most experienced centers proto-
cols is acceptable and functional, though not method-
ologically correct. Finally, the lack of  evidence suggests 
the enrollment of  as many patients as possible into well 
designed randomized trials.
Among the most significant HIPEC protocols, those 
based on Oxaliplatin in the perfusate have to be report-
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ed. From first demonstrations of  the rationale[152] and 
the pharmacokinetic[153] during hyperthermic application, 
few phase Ⅱ trials included OXt in their protocols[145,154]. 
In particular, Elias et al[133] published a series of  24 pa-
tients treated with Oxaliplatin in the perfusate at 460 
mg/m2 in 2 L/m2, during 30 min at 43 ℃ and later a re-
vised protocol including 106 consecutive patients treated 
with lower dose of  oxaliplatin (360 mg/m2) combined 
with irinotecan (360 mg/m2) in 2 L/m2 of  5% dextrose, 
for the same time at 43 ℃. The usefulness of  the Irino-
tecan association is controversial and may be the cause 
of  an increased toxicity[155].
Starting from 1995, several attempts were done to 
clarify the relationship between the primary tumor pa-
thology and the outcome of  PCCRC: tumor site (ap-
pendix, colon and rectum), grading, nodal and liver 
metastases were analyzed[130,131,146,150,156-158]. Following the 
substantial failure of  this search (no strong correlation 
at several multivariate analysis), researchers lost their at-
tention on tumor demographic in more recent publica-
tion, maintaining some interest only for tumor size[159]. 
Moreover, earlier reports on HIPEC suffered from the 
very small number of  included patients, making any 
stratification impossible. However, beside their role as 
independent prognostic factors, tumor characteristics 
are mandatory to get a better stratification, given that 
the only outcome parameter used is the overall survival, 
whereas only few studies considered quality of  life and 
PC-free survival[160-162].
The combined treatment of  synchronous liver me-
tastases in patient with PCCRC is beyond the scope of  
this review, but this topic is strongly related to HIPEC: a 
variable percentage of  patients included in retrospective 
studies underwent at the same time liver resection and 
CRS[128-130,145,163,164]; the report of  a different impact of  
liver metastasis in patient accordingly to the CCR (with 
a significant prognostic negative value only for CCR-0 
patients) underlines the possible different meaning of  
these two types of  tumor spread (“local” vs “systemic”); 
even if  a liver metastasis is not considered an absolute 
but only a relative contraindication to HIPEC, it seems 
logical that all the randomized recently designed study 
on HIPEC should exclude cases with liver involvement.
Currently, the main research effort is forwarded to 
RCTs evaluating mandatory second-look surgery with 
CRS + HIPEC in patients at high risk of  developing 
PCCRC versus standard of  care (control arms)[165]. Back-
ground for this new field of  interest mainly are: increas-
ing importance assigned to metachronous PC in the 
natural history of  the tumor; definition of  parameters to 
estimate the risk of  secondary PC[166], including synchro-
nous completely resected PC, ovarian metastases, perfo-
rated primary tumor and in some experiences pT4 tumor, 
colon occlusion and positive peritoneal cytology[124,167]; a 
great percentage of  asymptomatic and work up negative 
high risk patients were diagnosed to harbor macroscopic 
PC during second look laparotomy at one year[168]. As 
expression of  the two main groups working on HIPEC 
for CRC (American and French), two different RCTs are 
enrolling patients to demonstrate the usefulness of  an 
early second look treatment for high risk patients to de-
tect and treat (with CRS + HIPEC) metachronous PC, 
with acceptable morbidity and mortality[165]. 
In summary, to date there is no level Ⅰ or Ⅱ evidence 
that HIPEC increases the survival of  patients with PC-
CRC when added to modern perioperative chemotherapy 
protocols. The role of  a complete cytoreduction, even if  
well recognized as beneficial and mandatory to allow a 
rational use of  HIPEC, is not supported by RCTs.
In this lack of  evidence, there are two opposite at-
titudes: the NCI does not even mention HIPEC among 
the treatment options, while the French guidelines rec-
ommended it in the treatment of  patients with PC from 
CRC.
Beside its role as prognostic factor, the PCI is a fun-
damental tool to guide toward a tailored therapy, shifting 
from the idea of  a threshold value to a parameter inte-
grating with every tumor biology data and the clinical 
status of  the single patient.
The next goal will be the demonstration of  the use-
fulness of  the “second-look strategy” for high risk pa-
tients in terms of  overall survival and PC-free survival.
CONCLUSION
Peritoneal carcinomatosis is a real challenge for oncolo-
gists and surgeons, which treatment is very difficult. 
Many surgeons and oncologists are still use to raise the 
white flag in discovering them. The loco-regionality of  
PC and the real characteristic and barrier ability of  peri-
toneum with its proper lymphatic system have not still 
sufficiently investigated.
Substantial differences exist in treating the different 
form of  PC from different diseases among different 
centers and countries. Consequently different evidences 
in results still remain and are undoubtedly discussed. For 
this reason the chemosurgery (association of  chemo-
therapy and surgery as one entity) is not yet considered 
as a definitive valid option.
The different forms of  PC from different diseases 
should not continue to be treated in unique centers. 
Advanced diseases should be centralized in all countries, 
and centers performing chemosurgery should not con-
tinue to treat all diseases, but disease-specialized centers 
should start to apply chemosurgery to the different 
forms of  PC. The major risk is to lose the link between 
the PC and the primary tumor: waiting for a better un-
derstanding of  the peritoneal diffusion pathophysiology 
and trying to redefine its prognostic role, it would be 
prudent to mention the pathological classification of  the 
primitive tumor, that is frequently missed.
Lastly, to increase knowledge and overcome the actual 
limits, we all need a big effort toward a multidisciplinary 
approach, selection and discussion of  the different cases 
with a reciprocal knowledge increase. More importance 
and credit should be given to translational medicine. 
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